Akari Therapeutics is a clinical-stage biopharmaceutical company that develops advanced therapies for autoimmune and inflammatory diseases. Their lead product candidate is nomacopan, a second-generation complement inhibitor that prevents several inflammatory and prothrombotic activities. The company is based in London, UK.